Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2024-204881

Published: 2024

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2023-188925

Published: 2023

Journal Articles

Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma

Yuan Xia, Run Zhang, Yuanyuan Jin, Qinglin Shi, Yujie Wu, Jianyong Li, Lijuan Chen

Blood (2022) 140 (Supplement 1): 10015–10016.

https://doi.org/10.1182/blood-2022-166622

Published: 2022

Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study

Huayuan Zhu, Hui Shen, Yilian Yang, Chong-Yang Ding, MD, Yeqin Sha, Hongling Mi, Jingyan Qiu, Ruize Chen, Yujie Wu, Chun Qiao, Li Wang, MD, Lei Fan, MD PhD, Wei Xu, MD PhD, Jianyong Li, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141747

Published: 2020

Journal Articles

Reactivation of Hepatitis B Virus Infection in Aplastic Anemia Patients Receiving Immunosuppressive Therapy

Hua Yin, Suli Wang, Xingyu Lu, Wenyi Shen, MD, Ruinan Lu, Yu Zhu, MD PhD, Kourong Miao, Ming Hong, MD PhD, Shuai Wang, MD PhD, Jianfu Zhang, Chun Qiao, Yujie Wu, Xuemei Wu, Guangsheng He, Jianyong Li, MD PhD

Blood (2018) 132 (Supplement 1): 5107.

https://doi.org/10.1182/blood-2018-99-118836

Published: 2018

Journal Articles

Differential Diagnosis of Lymphoid Enhancer-Binding Factor 1 Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders

Lei Fan, MD, PhD, Tingmei Shen, Rong Wang, Yi Miao, Yujie Wu, Hui Yang, Li Wang, Wei Xu, Jianyong Li, MD PhD

Blood (2015) 126 (23): 4148.

https://doi.org/10.1182/blood.V126.23.4148.4148

Published: 2015

Journal Articles

Assessment of Bone Marrow Mesenchymal Stem Cells Biological Characteristics in Patients with Polycythemia Vera

Xiaoyan Zhang, Jianyong Li, MD, PhD, Hua Lu, MD, PhD, Yujie Wu, Jun Xia, Limin Duan, Yaping Zhang

Blood (2008) 112 (11): 4585.

https://doi.org/10.1182/blood.V112.11.4585.4585

Published: 2008

Journal Articles

Chronic NK Cell Leukemia with Haemophagocytic syndrome: Case Report and Literature Review

Hua Lu, Wenyi Shen, Jianfu Zhang, Yujie Wu, Jianyong Li, MD, PhD

Blood (2008) 112 (11): 4970.

https://doi.org/10.1182/blood.V112.11.4970.4970

Published: 2008

Journal Articles

In Vitro Aging of Rat Mesenchymal Stem Cells.

Xiaoyan Zhang, Jianyong Li, Yujie Wu, Jun Xia, Yaping Zhang, Hua Lu

Blood (2007) 110 (11): 4066.

https://doi.org/10.1182/blood.V110.11.4066.4066

Published: 2007

Journal Articles

Prognostic Significance of Molecular Cytogenetics in Chinese Patients with Chronic Lymphocytic Leukemia: A Prospective Unicentric Analysis.

Wei Xu, MD, PhD, Jianyong Li, MD., PhD., Li Li, MD., Yujie Wu, MD, Hui Yu, MD, Hongxia Qiu, MD., PhD., Lei Fan, MD., PhD., Changgeng Ruan, MD., PhD.

Blood (2007) 110 (11): 4690.

https://doi.org/10.1182/blood.V110.11.4690.4690

Published: 2007

Journal Articles

CD38 as a Prognostic Factor in Chinese Patients with Chronic Lymphocytic Leukaemia.

LI Jianyong, MD, PhD, Wei Xu, MD., PhD., Yujie Wu, MD., Lei Fan, MD., PhD., Hongxia Qiu, MD., PhD., Changgeng Ruan, MD., PhD.

Blood (2007) 110 (11): 4691.

https://doi.org/10.1182/blood.V110.11.4691.4691

Published: 2007

NARROW

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study

Reactivation of Hepatitis B Virus Infection in Aplastic Anemia Patients Receiving Immunosuppressive Therapy

Differential Diagnosis of Lymphoid Enhancer-Binding Factor 1 Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders

Assessment of Bone Marrow Mesenchymal Stem Cells Biological Characteristics in Patients with Polycythemia Vera

Chronic NK Cell Leukemia with Haemophagocytic syndrome: Case Report and Literature Review

In Vitro Aging of Rat Mesenchymal Stem Cells.

Prognostic Significance of Molecular Cytogenetics in Chinese Patients with Chronic Lymphocytic Leukemia: A Prospective Unicentric Analysis.

CD38 as a Prognostic Factor in Chinese Patients with Chronic Lymphocytic Leukaemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only